Canada Anti-Hypertensive Drugs Market to be Led by Calcium Channel Blockers Through 2028
The Canada
anti-hypertensive drugs market is likely to be driven by the rising prevalence
of hypertension during the forecast period.
According to the TechSci Research report,
titled “Canada Anti-Hypertensive
Drugs Market - By Region, Competition, Forecast and Opportunities, 2028,” the anti-hypertensive drugs market in Canada is anticipated to grow at an
impressive rate over the forecast period. This can be ascribed to the increase
in the prevalence of hypertension among people due to the lack of exercise and
excessive work pressure along with rising awareness about hypertension
diagnostics across the region. Similarly, increasing funding from private and
government organizations for the development of the healthcare sector and
research centers, and a rise in demand for alternative drugs for treatments are
expected to propel the Canada anti-hypertensive drugs market during the
forecast period.
Additionally, the
rise in the number of drug approvals is expected to create lucrative
opportunities for market players in the coming years. Besides, technological
advancements, such as the growing demand for telemedicine, are further expected
to support the Canada anti-hypertensive drugs market in the near future. However, the availability of generic anti-hypertensive drugs
has put pressure on the prices of branded drugs which can create affordability
issues thereby slowing down the growth of the market over the next few years.
Similarly, The Canadian regulatory environment is becoming increasingly
stringent, making it harder for pharmaceutical companies to obtain approval for
new drugs, which may hamper the market’s growth during the forecast period. Also,
the cost of developing new drugs has been increasing steadily over the years,
which could discourage pharmaceutical companies from investing in research and
development, restricting the market from rising smoothly.
Browse over XX market data
Figures spread through 70
Pages and an in-depth TOC on the "Canada Anti-Hypertensive Drugs Market”
The Canada anti-hypertensive
drugs market can be segmented by therapeutic class, type, distribution channel,
and region.
Based on therapeutic class, the market can be
segmented into diuretics, ACE inhibitors, ARBs, calcium channel blockers, beta
adrenergic blockers, renin inhibitors, vasodilators, and others. The calcium channel blockers segment dominated
the market in 2022 and is expected to remain dominant throughout the forecast
period. Key factors behind this segment’s dominance are the lesser side effects
exhibited by these drugs compared to the other type of antihypertensive drugs and
the rising awareness about the benefits they offer, such as a positive impact
on overall health and the decrease in the progression of kidney diseases, across
the region.
Based on distribution channel, the market can
be segmented into retail pharmacy, hospital pharmacy, e-commerce
websites, and online drug stores.
The hospital pharmacy segment is expected to dominate the market during the
forecast period on account of the rise in the number of hospitals across the
region, availability of specialized healthcare professionals in the hospitals,
and the surge in the use of the Internet across the region.
Major companies operating in the Canada Anti-Hypertensive
Drugs Market are:
- Pfizer Canada Inc
- Merck Canada Inc.
- AstraZeneca Canada Inc
- Novartis Pharmaceuticals Canada
Inc
- Sanofi-Aventis Canada Inc.
- Boehringer Ingelheim (Canada)
Ltd.
- Bristol-Myers Squibb Canada.
- Takeda Canada Inc.
- Teva Canada Ltd.
- Servier Canada Inc.
In March 2022, Pfizer Inc. recalled a blood
pressure drug due to elevated levels of a potentially cancer-causing impurity.
Download Free Sample Report
Customers can also request
10% free customization on this report.
“The easy
availability of anti-hypertensive drugs and the growing incidence of
hypertension in Canada have been significantly fueling the demand for
anti-hypertensive drugs in the country. The market is also gaining from the availability
of better treatment alternatives and the introduction of new drugs. Besides, the
increasing acceptance of new anti-hypertensive drugs, growing awareness regarding
the use of antihypertensive drugs, and the constantly evolving life science
industry in the region are projected to create lucrative opportunities for market
players over the next few years,” said Mr. Karan Chechi, Research Director at TechSci
Research, a research-based global management consulting firm.
Canada Anti-Hypertensive Drugs Market by
Therapeutic Class (Diuretics, ACE inhibitors, ARBs, Calcium Channel Blockers,
Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type
(Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail
Pharmacy, Hospital Pharmacy, E-commerce Websites, Online Drug Stores) and By
Region and Competition, Forecast & Opportunities, 2028 has
evaluated the future growth potential of Canada Anti-Hypertensive Drugs Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision-makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the Canada anti-hypertensive drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com